$10,000 invested in Pro Medicus and CSL shares 3 years ago is now worth…

Was I better off investing $10,000 into Pro Medicus or CSL shares three years ago?

Pro Medicus Ltd (ASX: PME) and CSL Ltd (ASX: CSL) shares are among the most heavily traded S&P/ASX 200 Index (ASX: XJO) healthcare shares.

But they've delivered some very disparate returns over the past three years.

One of the ASX healthcare juggernauts has smashed the 22.4% returns delivered by the ASX 200 since 22 September 2023, while the other materially trails that performance.

So, if you'd bought $10,000 worth of Pro Medicus and CSL shares three years ago, how much would you have now?

I'm glad you asked!

Two scientists analysing results on a computer screen.

Image source: Getty Images

Tipping $10,000 into CSL shares

On 22 September, shares in the ASX 200 biotech giant closed the day trading for $252.15 each.

Meaning for $10,000 you could have bought 39 CSL shares, with enough change left over to take your partner out to dinner. For the next 10 or so months, you would have watched those shares march higher.

But by August 2024, the ASX 200 healthcare share came under sustained selling pressure.

On Thursday, CSL shares were swapping hands for $179.09 apiece. Meaning those 39 shares you bought three years ago for $10,000 would be worth $6,985 today.

Now, we shouldn't entirely discount the CSL dividends.

If you owned the stock for the past three years you would have received (or shortly will) the past six unfranked dividend payments, totalling $12.55 a share. CSL stock traded ex-dividend on 9 September. If you owned shares at market close on 8 September, you can expect to receive the final FY 2026 dividend of $2.244 a share on 2 October.

So, if we add that $12.55 of passive income back into the recent share price, then the accumulated value of the CSL shares you bought three years ago is now worth $191.64. And the 39 shares you invested $10,000 into are worth $7,474.

Which brings us to…

Buying Pro Medicus shares in September 2023

Three years ago, shares in the ASX 200 health imaging company closed the day trading for $71.67 apiece.

Meaning your $10,000 investment would have netted you 139 shares, with enough change for popcorn and a movie.

On Thursday, Pro Medicus shares were changing hands for $159.52 each. So those 139 shares are worth $22,173 today.

And, as with CSL shares, you'd also have received (or shortly will) the last six fully franked Pro Medicus dividend payments, totalling $1.64 a share. Pro Medicus stock traded ex-dividend on 7 September. If you owned shares on 4 September, you can expect that record high 37 cent per share final dividend to land in your bank account on 29 September.

Now, if we add that passive income back into the recent share price, then the accumulated value of the 139 Pro Medicus shares you bought three years ago for $10,000 is now worth $22,401.

Which sees Pro Medicus clearly top CSL shares as the better investment over the past three years.

Motley Fool contributor Bernd Struben has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has positions in and has recommended CSL. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has recommended Pro Medicus. The Motley Fool Australia has recommended CSL and Pro Medicus. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Healthcare Shares

A female scientist in a laboratory setting using a tablet to review data, with a male scientist working in the background.
Healthcare Shares

Down 44%: Will you regret not buying Pro Medicus shares?

The shares have fallen hard, but the business itself continues to grow at an impressive rate.

Read more »

Two colleagues looking at a graph and comparing share prices.
Healthcare Shares

CSL shares: Buy, hold, or sell?

The shares have recovered sharply, so I wanted to see whether the valuation still stacks up.

Read more »

Two colleagues looking at a graph and comparing share prices.
Healthcare Shares

Telix vs Clinuvel Pharmaceuticals: Which ASX healthcare share deserves your next $1,000 of investment capital?

We compare Telix and Clinuvel Pharmaceuticals on valuation, dividends, and momentum—which ASX healthcare stock looks more compelling now?

Read more »

Numerous Australian dollar notes laid out.
Healthcare Shares

I'd buy 6,462 shares of this ASX stock to aim for $200 a month of passive income

This business can provide very healthy dividends.

Read more »

A doctor appears shocked as he looks through binoculars on a blue background.
Healthcare Shares

UBS thinks Telix Pharmaceuticals shares will go how high?

Good news out of the US has led to a share price target upgrade.

Read more »

Scientist taking down notes from a tablet, with two other scientists working in the background.
Healthcare Shares

Healius vs Australian Clinical Labs: Which ASX pathology share wins?

Healius and Australian Clinical Labs are both top pathology providers, but one stands out for profits, dividends, and recent momentum.

Read more »

Doctor looks at a graph on a tablet.
Healthcare Shares

Ramsay Health Care vs Sonic Healthcare: Which healthcare stock is better value?

Which offers better value — Ramsay Health Care or Sonic Healthcare? I compare their fundamentals, dividends, momentum and reveal my…

Read more »

A doctor looks unsure.
Healthcare Shares

CSL shares jump 93%: Is the ASX biotech stock a buy, sell or hold for October?

Can the CSL share price rebound keep going?

Read more »